The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia

NCT01507480 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Rendu Osler Disease
Telangiectasia, Hereditary Hemorrhagic

Interventions

DRUG: Bevacizumab

Sponsor

Hospices Civils de Lyon